HER2/NEU NEGATIVE

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) is better than capecitabine at preventing breast cancer from coming back in people with a specific type of triple-negative breast cancer (basal-like) that was not completely removed by initial chemoth…

This phase 3 trial tested whether adding the drug entinostat to standard hormone therapy (exemestane) helps people with advanced hormone receptor-positive breast cancer live longer without their cancer growing. The study included 608 adults whose breast cancer had spread locally …

This study tested a two-drug chemotherapy combination (carboplatin and nab-paclitaxel) given before surgery to people with locally advanced or inflammatory triple negative breast cancer. The goal was to shrink tumors enough so that no cancer remains at the time of surgery (called…

This study tests two drug combinations (olaparib plus either vistusertib or capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The goal is to find the safest dose and see if the drugs can control tumor growth. About 159 adults…

This early-phase study tested a vaccine (p53MVA) plus the drug pembrolizumab in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the combination is safe and can boost the immune system to attack cancer cells. Participant…

This study tests whether the drug ixabepilone can help people with HER2-negative breast cancer whose tumors didn't fully disappear after standard chemotherapy. About 116 participants will either receive ixabepilone or be observed. The goal is to see if the drug can stop cancer fr…

This study tested whether giving chemotherapy (paclitaxel and cyclophosphamide) with or without the targeted drug trastuzumab before surgery helps shrink breast cancer tumors in 92 women with early-stage or locally advanced breast cancer. The goal was to see if the treatment redu…

This study tests whether the immunotherapy drug pembrolizumab can help control advanced breast cancer in patients whose disease has not worsened after initial chemotherapy. It includes 71 adults with either inflammatory breast cancer or triple-negative breast cancer that has spre…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can increase immune cell activity in breast tumors. It involves 46 people with locally advanced HER2-negative breast cancer, divided by hormone receptor status. The…

This study tests whether giving radiation therapy before surgery can shrink tumors in people with hormone receptor-positive, HER2-negative breast cancer. The goal is to make the tumor smaller so less healthy tissue needs to be removed during surgery. The trial involves 25 adults …

This study compares two different chemotherapy combinations given before surgery for a fast-growing, hard-to-treat type of breast cancer called triple-negative inflammatory breast cancer. Researchers want to see if adding a targeted drug called panitumumab to standard chemotherap…

This study tests whether a special PET scan called FES can predict how well hormone therapy will work in people with newly diagnosed breast cancer that has spread. About 99 participants will get the scan, which uses a radioactive form of estrogen to "light up" cancer cells. The g…

This study looks at whether advanced breast imaging scans can predict how well chemotherapy is working in people with triple negative breast cancer. About 96 participants will get special MRI and molecular breast imaging scans before, during, and after chemo. The goal is to see i…

This study looks at whether watching an online genetics video, with or without phone counseling, helps reduce stress about cancer risk in women with triple-negative breast cancer. About 5,200 women aged 30 or older who have at least one ovary and a history of early or triple-nega…